Emerson Y. Chen

Dr. Emerson Y. Chen

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in JAMA Internal Medicine
Verified
Journal Article
Closed access
PDF file
ECEmerson Y. Chen
Emerson Y. Chen
VRVikram Raghunathan
Vikram Raghunathan
VPVinay Prasad
Vinay Prasad
Importance Approximately one-third of cancer drugs are approved based on response rate (RR)—the percentage of patients whose tumors shrink beyond an arbitrary threshold—typically assessed in a single-arm study. Objective To characterize RR end points used by the US Food and Drug Administration (FDA) for cancer drug approval. Design, Setting, and Participants A retrospective review of FDA-approved drug indications in oncology from 2006 to 2018. Exposures Data related to cancer type, line of therapy (first-line, second-line, or third-or-later-line treatment for advanced/metastatic disease), type of FDA approval pathway, trial design, sample size, and level of innovation were extracted. Main Outcomes and Measures The primary outcome was the RR used as the basis for FDA approval. The secondary outcome was rate of complete response. Results Eighty-five indications for 59 cancer drugs were identified, 32 (38%) received regular approval, and 53 (62%) were granted accelerated approval. Twenty-nine (55%) accelerated approvals were later converted to regular approval. Of these, 6 (21%) approvals showed overall survival benefit, 16 (55%) later established progression-free survival benefit, and 7 (24%) continued to use RR but gained regular approval. The median RR among the 85 indications was 41% (interquartile range [IQR], 27%-58%). Among them, 14 of 85 (16%) had an RR less than 20%, 28 of 85 (33%) had an RR less than 30%, and 40 of 85 (47%) had an RR less than 40%. The median complete RR for 81 participants was 6% (IQR, 2%-22%). The median sample size among studies leading to approval was 117 (IQR, 76-182; range, 18-1052 participants). Drugs with accelerated approval pending confirmatory data had lower RR compared with drugs that have completed most postmarketing efficacy requirements (median, 28%; IQR, 15%-50% vs median, 42%; IQR, 31%-58%;P = .02). Conclusions and Relevance Many cancer drugs approved on the basis of response rate offer numerically low or modest response rates. Most premarket studies accrue more than 100 patients. Some of these drugs could potentially be tested in premarket randomized clinical trials measuring directly end points that demonstrate clinical benefit.

1 June 2020 in JAMA Internal Medicine
Verified
Journal Article
Closed access
PDF file
ECEmerson Y. Chen
Emerson Y. Chen
AHAlyson Haslam
Alyson Haslam
VPVinay Prasad
Vinay Prasad
The US Food and Drug Administration (FDA) approves cancer drugs based on direct measures of patient benefit—such as overall survival (OS) or quality of life—or surrogate measures, such as change in biomarker level or tumor size on imaging studies. Surrogate end points often have weak or unknown correlations with OS,1,2 and postmarketing studies are limited.3 A surrogate end point can be used repeatedly in a particular cancer setting, such as response rate (tumor shrinkage) in mantle cell lymphoma in 2013 (with ibrutinib and lenalidomide) and 2017 (with acalabrutinib) after it was accepted for the first time in 2006 (with bortezomib).4

1 December 2020 in European Journal of Cancer
Verified
Journal Article
Open access
KRKate Rosen
Kate Rosen
VPVinay Prasad
Vinay Prasad
ECEmerson Y. Chen
Emerson Y. Chen
Kaplan-Meier survival analysis, the cornerstone of evaluating efficacy of oncology drugs in randomised controlled trials (RCTs), assumes censored patients are neither healthier nor sicker than those followed. We sought to examine whether censoring patterns differ between the control and experimental arms in one oncology journal that mandates the reporting of the number of patients censored. In this retrospective review, proportion of censoring and study design data were gathered from RCTs published in The Lancet Oncology that reported Kaplan-Meier curves between May 2018 and August 2019. Differential censoring rates were analysed at the 1st, 3rd, 6th, and overall time points in each study. Analysis was stratified by curves reporting progression-free survival (PFS) or overall survival (OS) end-points. Of the 160 articles reviewed, 29 studies with 51 Kaplan-Meier curves were eligible. In both OS (N = 25) and PFS curves (N = 26), the absolute weighted difference in censoring between the control and experimental arms was initially positive, indicating more censoring in the control arm (first time point OS: 0.32%; PFS: 2.00%). The absolute difference then became negative, indicating more censoring in the experimental arm as time progressed (end-of-study OS: -7.54%; PFS: -9.09%). Differences in censoring between control and experimental arms of cancer RCTs suggest that there could be systematic bias present at various study time points that may influence key results. Further investigation is needed, as possible reasons include study assignment disappointment, inappropriate follow-up length, lack of efficacy, or intolerable toxicity, each predominant at specific time points after randomisation.

25 June 2020 in Future Science OA
Verified
Journal Article
Open access
EMEdward B Maldonado
Edward B Maldonado
SPScott Parsons
Scott Parsons
ECEmerson Y. Chen
Emerson Y. Chen
AHAlyson Haslam
Alyson Haslam
VPVinay Prasad
Vinay Prasad
Aims, patients & methods: In this retrospective review, we sought to estimate the proportion of patients in the USA with advanced or metastatic cancer who are eligible for and may respond to recomm... Lay abstract This retrospective review sought to estimate patients in the USA with advanced or metastatic cancer who are eligible for and may respond to recommended first-line cytotoxic chemotherap...

23 November 2022 in Surgery
Verified
Journal Article
Closed access
Thomas Lee SuttonThomas Lee Sutton
Thomas Lee Sutton
LWLiam H. Wong
Liam H. Wong
BWBrett S. Walker
Brett S. Walker
EDElizabeth N. Dewey
Elizabeth N. Dewey
RERobert Eil
Robert Eil
SMSkye C. Mayo
Skye C. Mayo

29 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
KMKristen McClellan
Kristen McClellan
ECEmerson Y. Chen
Emerson Y. Chen
AKAdel Kardosh
Adel Kardosh
CLCharles D Lopez
Charles D Lopez
Jaydira Del RiveroJaydira Del Rivero
Jaydira Del Rivero
GPGuillaume Joe Pegna
Guillaume Joe Pegna
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogenous group of malignancies originating from neuroendocrine cells of the gastrointestinal tract, the incidence of which has been increasing for several decades. While there has been significant progress in the development of therapeutic options for patients with advanced or metastatic disease, these remain limited both in quantity and durability of benefit. This review examines the latest research elucidating the mechanisms of both up-front resistance and the eventual development of resistance to the primary systemic therapeutic options including somatostatin analogues, peptide receptor radionuclide therapy with lutetium Lu 177 dotatate, everolimus, sunitinib, and temozolomide-based chemotherapy. Further, potential strategies for overcoming these mechanisms of resistance are reviewed in addition to a comprehensive review of ongoing and planned clinical trials addressing this important challenge.